Mehmet Akce

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy

Mehmet Asım Bilen, Dylan J. Martini, Yuan Liu et al. · Cancer · 2018 · 161 citations · Full text

Medicine, Immunology, Oncology +16

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Mehmet Asım Bilen, Julie M. Shabto, Dylan J. Martini et al. · BMC Cancer · 2019 · 125 citations · Full text

Medicine, Immunology, Oncology +17

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma

Shishir K. Maithel, Jessica M. Keilson, Hop S. Tran Cao et al. · Annals of Surgical Oncology · 2023 · 75 citations · Full text

Medicine, Oncology, Pharmacology +15

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Mehmet Akce, Yuan Liu, Katerina Zakka et al. · American Journal of Clinical Oncology · 2020 · 64 citations

Medicine, Immunology, Oncology +17